Plus, a webinar this Thursday for your top questions


To view this email online, paste this link into your browser:
[link removed]





DONATE ([link removed])

Cystic Fibrosis Foundation
4550 Montgomery Ave, Suite 1100N
Bethesda, Maryland 20814

www.cff.org ([link removed])

We are thrilled to share that the U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) ([link removed]) for children with cystic fibrosis ages 6 to 11 who have at least one copy of the F508del mutation or one copy of certain rare mutations.

With this approval, approximately 1,500 children will be eligible for a CFTR modulator for the first time. Today’s news is a significant step forward in our mission to help all people with CF lead long, fulfilling lives, as research suggests that beginning treatment with a modulator early could help slow or even prevent the irreversible progression of cystic fibrosis.

READ THE ANNOUNCEMENT ([link removed])

If you’re a parent or caregiver to a child with CF, join us for a community webinar from 7-8 p.m. ET on Thursday, June 10 ([link removed]), to have your top questions answered by experts from the Cystic Fibrosis Foundation. All those who register will receive a recording of the event.

SAVE YOUR SEAT ([link removed])

It is thanks to your participation in clinical trials and fundraising efforts that we have been able to reach this important milestone. Together, we will not stop until everyone has a treatment for the underlying cause of their disease.





4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US

This email was sent to [email protected].
To ensure that you continue receiving our emails,
please add us to your address book or safe list.

manage your preferences ([link removed])
opt out ([link removed]) using TrueRemove(r).

Got this as a forward? Sign up ([link removed]) to receive our future emails.
email powered by Emma(R)
[link removed]